Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nelson Stone

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Cancer|June 22, 2011
Impact of race on biochemical disease recurrence after prostate brachytherapyKosj Yamoah, Nelson Stone, Richard Stock
International Journal of Radiation Oncology, Biology, Physics|October 8, 2003
Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant qualityMarisa A Kollmeier, Richard G Stock, Nelson Stone
International Journal of Radiation Oncology, Biology, Physics|November 22, 2011
Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancerKevin Forsythe, Seth Blacksburg, Nelson Stone, et al.
International Journal of Radiation Oncology, Biology, Physics|December 6, 2011
Predictors of metastatic disease after prostate brachytherapyKevin Forsythe, Ryan Burri, Nelson Stone, et al.
BJUI Compass|April 27, 2022
Transperineal prostate biopsy identifies locations of clinically significant prostate cancer in men considering focal therapy with PI-RADS 3-5 regions of interestNelson Stone, Vassilios Skouteris, Samuel Chang, et al.
Brachytherapy|August 1, 2018
Prostate-specific antigen doubling time is a significant predictor of overall and disease-free survival in patients with prostate adenocarcinoma treated with brachytherapyLucas Resende Salgado, Ryan Rhome, William Oh, et al.
Brachytherapy|October 17, 2016
The impact of timing of salvage hormonal therapy on survival after brachytherapy for prostate cancerDaniel Sagalovich, Michael Leapman, John Sfakianos, et al.
Pathology, Research and Practice|August 4, 2009
Histological patterns and associated PSA levels for prostatic adenocarcinoma following brachytherapyGuang-Qian Xiao, Youming Huan, Nelson Stone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2002
13-cis retinoic acid and complete androgen blockade in advanced hormone-naive prostate cancer patients: report of a phase II randomized studyAnna C Ferrari, Nelson Stone, Richard Stock, et al.
The Journal of Urology|July 28, 2011
Methods of developing UWIN, the modified American Urological Association symptom scoreAl B Barqawi, Kathryn F Sullivan, E David Crawford, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Cancer|June 22, 2011
Impact of race on biochemical disease recurrence after prostate brachytherapyKosj Yamoah, Nelson Stone, Richard Stock
International Journal of Radiation Oncology, Biology, Physics|October 8, 2003
Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant qualityMarisa A Kollmeier, Richard G Stock, Nelson Stone
International Journal of Radiation Oncology, Biology, Physics|November 22, 2011
Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancerKevin Forsythe, Seth Blacksburg, Nelson Stone, et al.
International Journal of Radiation Oncology, Biology, Physics|December 6, 2011
Predictors of metastatic disease after prostate brachytherapyKevin Forsythe, Ryan Burri, Nelson Stone, et al.
BJUI Compass|April 27, 2022
Transperineal prostate biopsy identifies locations of clinically significant prostate cancer in men considering focal therapy with PI-RADS 3-5 regions of interestNelson Stone, Vassilios Skouteris, Samuel Chang, et al.
Brachytherapy|August 1, 2018
Prostate-specific antigen doubling time is a significant predictor of overall and disease-free survival in patients with prostate adenocarcinoma treated with brachytherapyLucas Resende Salgado, Ryan Rhome, William Oh, et al.
Brachytherapy|October 17, 2016
The impact of timing of salvage hormonal therapy on survival after brachytherapy for prostate cancerDaniel Sagalovich, Michael Leapman, John Sfakianos, et al.
Pathology, Research and Practice|August 4, 2009
Histological patterns and associated PSA levels for prostatic adenocarcinoma following brachytherapyGuang-Qian Xiao, Youming Huan, Nelson Stone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2002
13-cis retinoic acid and complete androgen blockade in advanced hormone-naive prostate cancer patients: report of a phase II randomized studyAnna C Ferrari, Nelson Stone, Richard Stock, et al.
The Journal of Urology|July 28, 2011
Methods of developing UWIN, the modified American Urological Association symptom scoreAl B Barqawi, Kathryn F Sullivan, E David Crawford, et al.
Pageof 2